Compare GSK plc (GSK) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs VNET Group Inc — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while VNET Group Inc trades at $7.4 (market cap $2.14B). The key difference: GSK plc is far larger — about 47.9× VNET Group Inc's market cap, and GSK plc pays a 3.57% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| GSK | VNET | |
|---|---|---|
Market Cap | $102.60B | $2.14B |
Sector | Health | Technology |
52-Week High | $61.18 | $14.03 |
52-Week Low | $38.22 | $6.29 |
Enterprise Value | $123.04B | $5.29B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
VNET trades at $7.40, down 1.07% today, with a neutral technical signal and bearish moving averages. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investor entry and AI-driven demand boosting wholesale data center growth.
The outlook is mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt pose risks. Investment opportunity hinges on execution of capacity expansion and AI demand, while investors face volatility from earnings misses and competitive pressures in China's data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
